Literature DB >> 6872343

Immunochemical characterization of anti-albumin antibodies in liver diseases.

D Onică, A Călugăru, I Mărgineanu, G Zamfir, I Belaşcu.   

Abstract

Anti-albumin antibodies (AAA) were isolated from sera of hepatic patients and normal individuals by affinity chromatography on insolubilized glutaraldehyde-treated human albumin. Anti-albumin antibodies were found to belong to IgG and IgM classes in both normal and hepatic patients. The normal level of AAA increased in pathologic conditions, the increase recorded for IgM AAA being higher than that for IgG AAA. The dissociation rate of AAA from the radiolabeled antigen in normal and hepatic sera showed that the affinity of AAA was higher in normal sera than in sera of patients with chronic liver disease and acute viral hepatitis. Anti-albumin antibodies were fractionated into two populations (AAA1 and AAA2) by a two-step chromatographic procedure. AAA1 and AAA2 were found different as regards their affinity for the antigen; specifically, AAA1 affinity was higher than that of AAA2. The other difference between AAA1 and AAA2 might stand in their specificity for the haptenic and structural determinants present in the glutaraldehyde-treated albumin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872343     DOI: 10.1016/0090-1229(83)90140-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera.

Authors:  M H Ravindranath; P I Terasaki; C Y Maehara; V Jucaud; S Kawakita; T Pham; W Yamashita
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

2.  Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus.

Authors:  Josephine Nehring; Lucia A Schirmbeck; Justa Friebus-Kardash; Denise Dubler; Uyen Huynh-Do; Carlo Chizzolini; Camillo Ribi; Marten Trendelenburg
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.